SCHEMBL4363585

SCHEMBL4363585

NC(=O)CN1CCN(c2ccc(C=CC(=O)O)cc2[N+](=O)[O-])CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 18/20 0.52
ALDH1A1 P00352 13/20 0.52
LMNA P02545 8/20 0.52
MAPK1 P28482 7/20 0.52
HTT P42858 4/20 0.52
TDP1 Q9NUW8 4/20 0.52
KMT2A Q03164 3/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
MEN1 O00255 2/20 0.52
L3MBTL1 Q9Y468 7/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
TP53 P04637 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 2/20 0.48
ALDH1A3 P47895 1/20 0.47
CYP3A4 P08684 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4363579 1.00 MAPT (0.52) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL2076697 0.86 MAPT (0.64) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL2079878 0.86 MAPT (0.49) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL7821117 0.84 MAPT (0.69) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL7821114 0.84 MAPT (0.69) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL3436159 0.79 MAPT (0.61) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL2080950 0.79 L3MBTL1 (0.63) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL2080668 0.79 MAPT (0.53) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL3436164 0.79 LMNA (0.54) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL3435561 0.79 MAPT (0.54) MAPTALDH1A1LMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 MAPT 1330/4885ALDH1A1 975/4885LMNA 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.